Sionna cancels PDUFA for drug candidate, cites business review
Sionna Therapeutics has voluntarily withdrawn its New Drug Application for STX001, which had a Prescription Drug User Fee Act date, to conduct a strategic business review. The company anticipates that the application will not be re-filed in its current form.
View filing at SEC.gov →